TAIYO HOLDINGS CO.,LTD.

This annual securities report provides a comprehensive disclosure of the business activities of the filing company and its affiliates. It consists primarily of 2 reportable segments: Electronics and Medical and Pharmaceuticals. The Electronics segment develops, manufactures and sells, and purchases and sells, chemical materials for electronic components, including PCB materials. The Medical and Pharmaceuticals segment manufactures and sells prescription drugs, provides contract manufacturing services, and manufactures and sells dental laboratory products. The report describes the organization, including domestic and overseas affiliates, its high overseas sales ratio, the launch of new products, the strengthening of its production structure, and the formulation and implementation of the long-term management vision Beyond Imagination 2030 and the medium-term management plan. The 7 basic policies of the long-term management vision include developing and utilizing autonomous talent, growing the Electronics business and creating new businesses, growing the Medical and Pharmaceuticals business, digital transformation (DX), creating new businesses, strategic M&A, and strengthening SDGs initiatives. Financial and business indicators, plans and measures for the fiscal years ending March 2022 through March 2026 are disclosed.